Method for primary prevention of allergic disorders during infancy through IgE-class-specific immunosuppression
The disclosure provides a pharmaceutical composition containing an anti-IgE antibody that suppresses the production of allergen-specific IgE antibodies and methods of use thereof.
1. A method of suppressing production of allergen-specific IgE antibodies in a subject during a fetal stage, a newborn stage, and/or infancy, comprising administering an effective amount of an anti-IgE antibody that binds to a Cε3 region of IgE to a mother pregnant with the subject; wherein the mother pregnant with the subject excludes mothers diagnosed with asthma; and the mother pregnant with the subject is not diagnosed with an allergic disorder.
2. The method according to claim 1 , wherein the subject is human.
3. The method according to claim 1 , wherein the subject is not diagnosed with asthma.
4. The method according to claim 1 , wherein the subject is not diagnosed with an allergic disorder.
5. The method according to claim 1 , wherein the method decreases a probability for an onset of an allergic disorder in the subject during infancy and later.
6. The method according to claim 1 , further comprising administering an allergen to the subject.
7. The method according to claim 6 , wherein the allergen is food allergen.
8. The method according to claim 6 , wherein the allergen comprises peanut.
9. The method according to claim 1 , wherein the anti-IgE antibody comprises omalizumab.
10. The method according to claim 1 , wherein the mother has not taken the anti-IgE antibody previously.
11. A method of suppressing production of allergen-specific IgE antibodies in a subject during infancy, comprising administering an effective amount of an anti-IgE antibody that binds to a Cε3 region of IgE to a mother pregnant with the subject; wherein the mother pregnant with the subject excludes mothers diagnosed with asthma; and wherein the mother pregnant with the subject is not diagnosed with an allergic disorder.
12. The method according to claim 11 , wherein the anti-IgE antibody comprises omalizumab.
13. The method according to claim 11 , wherein the mother has not taken the anti-IgE antibody previously.
14. The method according to claim 11 , wherein the subject is human.
15. The method according to claim 11 , wherein the subject is not diagnosed with asthma.
16. The method according to claim 11 , wherein the subject is not diagnosed with an allergic disorder.
17. The method according to claim 11 , further comprising administering an allergen to the subject.